 SOUTH SAN FRANCISCO, Calif., March 01, 2021 GLOBE NEWSWIRE -- Today, Annexon, Inc. Annexon Nasdaq: ANNX, a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced that patient dosing has begun in its Phase 2 ARCHER study of its anti-C1q therapy, ANX007, to treat Geographic Atrophy GA. GA, also known as atrophic age-related macular degeneration AMD or dry AMD, can lead to blindness caused by damaged and dying retinal cells. Currently, there are no approved treatment options to prevent onset or progression of GA. 